TMS for PTSD: what the FDA has cleared, what the research shows, and who might ask about it

The FDA line

What the FDA has cleared TMS for, and where PTSD fits

The FDA clears each TMS device for specific uses. Only one record we found names PTSD: the MeRT System, cleared June 3, 2026.

FDA records read October 29, 2026. Devices are cleared, not approved like drugs.

The 2026 PTSD clearance: the MeRT System

These details come from the FDA's summary for K260402. We did not find a journal article on the trial to check them against.

• How it works. Software analyzes a resting, eyes-closed brain-wave and heart recording (EEG/ECG) and picks a personal pulse rate between 8 and 13 Hz. A compatible TMS device then delivers it to the dorsomedial prefrontal cortex, at the front and middle of the brain. The software itself gives no stimulation.
• The course. 20 to 25 sessions, one a day, five days a week, about 30 minutes each.
• The trial. 158 adults with PTSD were assigned to real treatment (77) or sham (81), and 84% finished. The real-treatment group improved significantly more than sham on the self-rated PCL-5 checklist and the clinician-rated CAPS-5 interview. Its PCL-5 score fell 27 points on average. No serious side effects were reported.
• Its limits. The FDA summary says the trial was not designed to show whether the personal, EEG-based pulse rate matters compared with TMS at a fixed rate.
• Add-on only. It is cleared to be used alongside other PTSD treatment, not instead of it.

What “off-label” means for standard TMS

The clearance covers the MeRT System. It does not cover the standard depression settings used in many PTSD studies, including the large VA study below. The 2026 VA study notes that TMS is increasingly used off-label for PTSD, often with protocols developed for depression. The FDA's guidance for depression TMS devices still tells makers to note that safety and effectiveness have not been established in people with a history of PTSD. That is a caution, not a ban.

Two other PTSD-related devices are in the FDA's database, and neither is TMS. Modius Spero (Neurovalens, May 2026) is classified as a transcranial nerve stimulation device for PTSD-associated symptoms. NightWare (2020) is an Apple Watch therapy meant to reduce sleep disturbance from nightmares. The 2023 VA/DoD PTSD guideline lists NightWare among treatments with insufficient evidence to recommend for or against, in its recommendation 24 and again for nightmares in recommendation 33.

The evidence

What the research on TMS for PTSD shows

The newest studies point in different directions. Here is each one, with what it found and what limits it.

The 2026 residential trial (JAMA Network Open)

In a randomized trial published in April 2026, 119 military personnel and veterans with combat-related PTSD in a 30-day residential program were assigned to real or sham TMS on top of the program, which included Prolonged Exposure therapy twice a week. TMS was aimed using each person's MRI and delivered by a robotic arm, daily, for up to 20 sessions. Patients, staff and assessors did not know who had real TMS.

• At the end of treatment, the real-TMS group improved more on the self-rated PCL-5 (5.94 points more than sham) and on the clinician-rated CAPS-5 (6.03 points more).
• At follow-up, the PCL-5 advantage was larger: 12.30 points.
• Both groups improved a lot, because both had intensive therapy. 107 of the 119 (90%) were men. The lead author holds a patent on this navigated TMS method, licensed to a company in which he has equity, according to the paper's disclosures.

The 2026 meta-analysis of 16 trials

A 2026 meta-analysis pooled 16 randomized trials (786 people) comparing real TMS with sham. TMS showed a large, statistically significant effect on PTSD symptoms that people rated themselves. On clinician-interview scales the effect did not reach significance. The authors found large differences between trials, rated the evidence low or very low certainty, and wrote that the findings do not allow firm conclusions.

The Cochrane review of 13 trials (2024)

Cochrane reviews pool randomized trials. The 2024 review included 13 trials with 577 people. Its main finding: real TMS probably makes little to no difference to PTSD severity right after treatment (moderate-certainty evidence, from the 3 trials with usable data, 99 people). When more trials were added, results varied widely from study to study. Seven serious adverse events were reported (6 with real TMS, 1 with sham), and the review rated that evidence very uncertain. None of the trials reported remission right after treatment.

The VA study of 756 veterans (2026)

Researchers at VA hospitals in Providence and Palo Alto looked at the records of 756 veterans with both PTSD and depression who had TMS for their depression at more than 30 VA sites. They compared three common protocols, shown below (658 of the 756 veterans). PTSD scores dropped 18 to 22 points on the PCL-5, a standard self-report PTSD checklist. The VA's summary calls it the first study large enough to show statistically significant benefits for all three protocols.

Berlow et al., Brain Stimulation, 2026. “Response” means the PCL-5 score fell by more than 10 points. The last column is what the study calls remission: a final PCL-5 below 33. The PCL-5 is a self-report checklist, and the VA's National Center for PTSD says a score of 31 to 33 or more suggests probable PTSD, so below 33 means a person no longer scored in the probable-PTSD range. It is not a clinician's diagnosis.

*A caution about the deep TMS figure. The 78% response for deep TMS comes from 61 veterans treated with a depression protocol, with no sham group. In the larger of the two sham-controlled deep TMS trials for PTSD we found (2021, 125 people randomized, aimed at the middle of the front of the brain and paired with brief trauma reminders), PTSD scores improved less with real deep TMS than with sham: 16.3 versus 20.5 points on the CAPS-5 at five weeks. A 2013 pilot of 30 people had found a benefit on intrusive symptoms.

The VA study's limits matter. Every veteran also had depression, and they received TMS alongside other VA care. With no sham group, nobody knows how much of the change came from TMS itself; the authors say so.

Fast or slow stimulation?

Studies disagree on which speed works better. A 2022 review reported that fast stimulation did better, but the 2024 Cochrane review found slow (1 Hz) stimulation beat sham in a small subgroup while fast stimulation did not.

• Cochrane, 2024. Slow (1 Hz): a standardized difference of -1.32 in favor of real TMS (2 studies, 35 people). Fast (10 to 50 Hz): -0.06, no clear difference (5 studies, 216 people). The authors said these results should be interpreted with caution because of the much smaller slow-stimulation group and how the comparison was built.
• A civilian trial, 2020. In 31 civilians with PTSD, 1 Hz to the right front of the brain beat sham, and 10 Hz did not. 10 Hz appeared to help depressive symptoms.
• A veteran trial, 2019. 44 veterans were enrolled in a randomized trial of 1 Hz versus 10 Hz, both to the right prefrontal cortex, five days a week for six weeks plus a three-week taper. Both groups improved on PTSD and depression scores, and neither speed beat the other. There was no sham group.

Other trials worth knowing

• Theta burst, 50 veterans (2019). In a sham-controlled trial at the Providence VA, 10 daily sessions improved social and work functioning at two weeks. Self-reported PTSD symptoms improved too, but not by a statistically significant margin. At one month, after up to 10 more open-label sessions, PTSD symptoms were significantly better than with sham.
• TMS with Cognitive Processing Therapy, 103 veterans (2018). In a randomized trial, veterans had 1 Hz TMS to the right prefrontal cortex, or sham, just before each weekly CPT session, for 12 to 15 sessions. The real-TMS group had greater PTSD symptom reductions, lasting to six months. 60% completed treatment.

Why the results do not agree

1. Different settings. Studies stimulated the left, right or middle of the front of the brain, at slow (1 Hz) or fast (10 Hz and faster, or theta burst) rates.
2. Different amounts. Courses ran from 10 sessions to six weeks of daily sessions plus a taper, and some trials paired TMS with therapy or trauma reminders.
3. Different people. The Cochrane authors note that trials tended to enroll either mostly male veterans or mostly female civilians, and the share with depression varied a lot.
4. Different measures. The 2026 meta-analysis found an effect on self-rated PTSD scales but not on clinician interviews.

What the VA's treatment guideline says

The 2023 VA/DoD guideline for PTSD lists repetitive TMS among treatments with insufficient evidence to recommend for or against (recommendation 24). Among medicines, it recommends paroxetine, sertraline or venlafaxine. The 2026 studies above came out after that guideline.

How it might work

Where TMS is aimed in PTSD

PTSD is linked to changes in three brain networks, according to the 2022 review: the default mode, executive control and salience networks. The executive control network includes the dorsolateral prefrontal cortex at the front and side of the brain, where many PTSD studies aimed TMS, including the 1 Hz and 10 Hz trials above. The MeRT System and the deep TMS trial aimed at the middle of the front of the brain instead. Which target works best is still being tested.

Complex PTSD

TMS for complex PTSD (C-PTSD)

The VA's National Center for PTSD explains that complex PTSD is a separate diagnosis in the World Health Organization's ICD-11 but not in the DSM-5, which treats complex responses as part of PTSD. It was first proposed to capture the long-term effects of prolonged, early trauma such as child sexual abuse.

Research on TMS for complex PTSD is very thin. The only study found for this guide was a 2024 abstract from a private TMS company that reviewed the records of 31 treated patients, 21 of whom met complex PTSD criteria. Trauma symptom scores fell 45% on average across all 31, with no comparison group. That is a starting point, not proof. If you have complex PTSD, ask your psychiatrist how the proven PTSD treatments apply to you, and treat TMS as an open question.

Where it fits

TMS next to the proven PTSD treatments

TMS is not a replacement for trauma-focused therapy or the recommended medicines. Even the FDA-cleared MeRT System is cleared only as an add-on.

The National Center for PTSD names the options with the most support:

• Trauma-focused talk therapy: Cognitive Processing Therapy (CPT), Eye Movement Desensitization and Reprocessing (EMDR) and Prolonged Exposure (PE), usually about 8 to 16 sessions.
• Medication: paroxetine, sertraline and venlafaxine have the most evidence.

In the positive trials above, TMS was added to therapy: just before weekly CPT sessions in the 2018 veteran trial, and alongside Prolonged Exposure in the 2026 residential trial.

Who might reasonably ask about TMS

• People with PTSD and depression, when the depression has not improved enough on an antidepressant. TMS is FDA-cleared for that depression, and the large VA study was in people with both.
• People who could not tolerate antidepressant side effects.
• People who have tried trauma-focused therapy and still have symptoms, as a conversation with their psychiatrist, including whether the FDA-cleared MeRT System is a fit.

Safety

Side effects and who usually cannot have TMS

Seizure is the most serious known risk of TMS. International safety guidelines from 2009 say seizures have been extremely rare since the first safety limits were published in 1998, and that most of the few new cases involved stimulation beyond those limits, often in people taking drugs that lower the seizure threshold. The 2021 update says the risk is low, even in people taking medicines that act on the brain, with standard settings. The more common side effects, such as scalp discomfort and headache, are covered in our TMS side effects guide.

Labyrinth Psychiatry Group's TMS page lists the usual exclusions: a seizure disorder or history of seizures, metal or electronic devices in or near the head (such as deep brain stimulators, cochlear implants, aneurysm clips or stents), implanted heart devices close to the coil, head tattoos made with metallic ink, and certain neurological conditions such as a severe head injury. The FDA's 2018 OCD announcement also lists bullet fragments among the metal objects in or near the head that rule out that device.

Insurance

Insurance and cost for TMS when PTSD is the reason

Coverage usually runs through a depression diagnosis. Aetna's published policy, for example, covers TMS for major depression when its criteria are met and calls TMS for PTSD experimental. Ask your plan for the policy that applies to you.

• Aetna lists post-traumatic stress disorder among the conditions for which it considers TMS experimental, investigational or unproven (Clinical Policy Bulletin 0469, last reviewed July 17, 2026).
• The same policy also lists Magnetic e-Resonance Therapy (MeRT) for PTSD as experimental, even though it was last reviewed after the June 2026 FDA clearance.
• For depression, the same policy allows up to 30 sessions over six weeks plus 6 tapering sessions when its criteria are met.
• With PTSD and depression,approval depends on the depression meeting your plan's rules.

For the numbers, read our TMS cost and insurance guide, and if you have met your deductible, our guide to TMS before the deductible resets.